Drug Combo’s Response Rates Top 90% in Small Cell Lung Cancer Trial
Up to 90% of patients with advanced small cell lung cancer (SCLC) responded to a PD-L1/VEGF bispecific antibody linked to an antibody-drug conjugate (ADC), a preliminary trial showed. Response rates ranged from 52.4% in patients who received pumitamig/elfetabart drozuntecan (elfe-D) as third-line therapy to 92.3% in those who received the novel therapy in first line. […]
Promising New Treatment Reduces Mortality Risk in Squamous Lung Cancer
Introducción a los resultados del ensayo El tratamiento de segunda línea con una inmunoterapia anti-CTLA-4 en investigación mejoró la supervivencia en pacientes con cáncer de pulmón no microcítico escamoso (NSCLC) en comparación con la quimioterapia, según los resultados del ensayo de fase III PRESERVE-003. Entre los pacientes metastáticos que progresaron tras el tratamiento con inhibidores […]
Significant Trial Findings on DOACs for Lower-Risk Atrial Fibrillation Patients
Resultados del ensayo Nuevos datos aleatorizados sugieren que la anticoagulación oral es beneficiosa para pacientes de bajo riesgo con fibrilación auricular (Afib), según los investigadores. Entre los pacientes con Afib y un factor de riesgo tromboembólico en el ensayo SINGLE-AF, la terapia con anticoagulantes orales directos (DOAC) redujo el riesgo de eventos cardiovasculares compuestos a […]
Reflexiones sobre la Investigación del Autismo en un Tiempo de Avances Científicos
Nueva Perspectiva en la Ciencia del Autismo Recientemente, un estudio pionero destacó el avance significativo en la investigación sobre el autismo, señalando nuevas fronteras científicas. Sin embargo, el Comité Interagencial de Coordinación del Autismo (IACC), durante su reunión más reciente, se centró en hipótesis que ya habían sido ampliamente investigadas y descartadas. La discrepancia es […]
Understanding the Continuing Challenge of HIV Despite Advances
Current State of HIV Last week, the United Nations (UN) issued a declaration renewing its call to eliminate HIV/AIDS by 2030, with a focus on increasing spending to eradicate the disease, particularly in lower- and middle-income countries. It is important to note that the U.S. was one of the eight countries that did not endorse […]
Increased Risk of HPV-Related Cancers in HIV and Transplant Patients
People living with HIV and recipients of solid organ transplants have a significantly higher risk of developing cancers associated with human papillomavirus (HPV), namely anal, penile, vulvar, and cervical cancers. This conclusion comes from a retrospective case-control study conducted in Sweden. According to findings reported by Christina Carlander, MD, PhD, from the Karolinska Institutet in […]
GLP-1 Agonists May Improve Longevity in Individuals with Severe Mental Illness
Starting a GLP-1 receptor agonist was associated with significantly lower risks of death and cardiovascular events in adults with serious mental illness (SMI), a target trial emulation showed. Among 195,184 propensity score-matched pairs of adults with SMI, GLP-1 drug initiators had a 24% lower 4-year mortality risk compared with SGLT2 inhibitor initiators (HR 0.76, 95% […]
Impact of Hormone Replacement Therapy Timing on Dementia Risk in Postmenopausal Women
Hormone replacement therapy (HRT) has been linked to a reduced risk of dementia according to a prospective study involving nearly 185,000 postmenopausal women in the U.K. Biobank. After 13 years of follow-up, results indicated that HRT use was associated with a lower risk of all-cause dementia with a hazard ratio (HR) of 0.90 (95% CI […]
CT Angiography Not Recommended After Heart Attack Exclusion
After ruling out a myocardial infarction (MI) in patients with suspected acute coronary syndrome (ACS), routine use of CT coronary angiography to guide management did not reduce subsequent cardiac events compared with standard care, results of a randomized trial showed. Over a median of 3 years in the TARGET-CTCA study, the primary composite outcome of […]
Trial Tentatively Backs DOACs After TAVR
In a departure from other transcatheter aortic valve replacement (TAVR, or TAVI) trials, direct oral anticoagulant (DOAC, or NOAC) therapy seemed to safely prevent subclinical leaflet thrombosis in ACASA-TAVI — but not convincingly enough to change practice. Among people randomized to DOAC monotherapy, the incidence of hypoattenuated leaflet thickening at 12 months (HALT; detected on […]